[Expert Advice] How Device Lawyers Prove Combination Product Failures (Hardware Plus Medication)
#Expert #Advice #Device #Lawyers #Prove #Combination #Product #Failures #Hardware #Plus #MedicationMalpractice includes using products and hardware that can break. Get help from me. lawyer rights by Jones Law Group
Title: Malpractice includes using products and hardware that can break. Get help from me. lawyer rights
Channel: Jones Law Group
[Deep Dive] Failure To Perform Timely C-Section In Shoulder Dystocia Emergencies: Legal Analysis
[Expert Advice] How Device Lawyers Prove Combination Product Failures (Hardware Plus Medication)
The Anatomy of a Nightmare: What is a Combination Product?
I remember sitting in a windowless conference room in Chicago back in 2014, staring at a plastic bag containing a spent, bloody autoinjector. My client, a father of three who relied on that specific device to manage his severe, fast-onset autoimmune flare-ups, had done everything right. He pulled the cap, pressed the injector against his thigh, heard the reassuring "click," and waited the full ten seconds. But instead of the therapeutic biologic drug entering his muscle tissue, a microscopic mechanical misalignment inside the device caused the internal glass syringe to shatter under the immense pressure of the spring. The drug leaked into the plastic housing, and he received nothing but a superficial metal scratch. Within hours, he was in systemic shock. That was my baptism by fire into the world of combination product failures—a domain where biochemistry and mechanical engineering are forced into a shotgun wedding, and where patients pay the price when things go wrong.
To understand these cases, you have to realize that a combination product is not simply a drug, nor is it simply a medical device. Under the FDA’s regulatory definition in 21 CFR Part 3, these are hybrid entities. They are autoinjectors prefilled with monoclonal antibodies, drug-eluting cardiovascular stents, insulin pens, transdermal patches with active chemical delivery systems, and prefilled syringes. They represent a massive leap forward in patient convenience, allowing complex therapies to be self-administered at home rather than in a clinical setting. But this convenience masks an incredible, terrifying layer of technical complexity. When a patient uses an autoinjector, they are initiating a rapid cascade of physical and chemical events that must occur in perfect, microsecond sequence. If a single plastic tooth is off by a fraction of a millimeter, or if the drug’s viscosity changes by a few centipoise, the entire system fails catastrophically.
As a trial lawyer, you quickly learn that these cases are legal minefields because they defy traditional product liability categories. If you treat a combination product failure as a simple drug case, the manufacturer’s defense team will bury you in clinical trial data proving the molecule itself is safe and effective. If you treat it as a simple device case, they will show you millions of perfectly molded plastic shells that passed quality control. The magic—and the danger—lies entirely at the interface. It is the physical, chemical, and mechanical interaction between the drug and the hardware that holds the key to proving liability. You have to become part toxicologist, part mechanical engineer, and part regulatory historian to even stand a chance of surviving a motion to dismiss.
The legal landscape for these hybrid products is further complicated by the split personality of the regulatory frameworks that govern them. The FDA has historically struggled to regulate these products because its internal divisions are siloed. The Center for Drug Evaluation and Research (CDER) looks at molecules; the Center for Devices and Radiological Health (CDRH) looks at hardware. When a combination product is submitted for approval, the FDA assigns a "lead center" based on the product's primary mode of action (PMOA). This jurisdictional handoff creates regulatory blind spots that sophisticated manufacturers are all too eager to exploit. They will use the FDA's own internal siloes to shield themselves from rigorous cross-disciplinary testing, leaving the market—and the consumer—to serve as the ultimate, unpaid beta testers.
To win these cases, your primary objective is to break down these artificial divisions. You must demonstrate to a jury that the drug and the device are not two separate components working in tandem, but a single, integrated medical system. When that system fails, it is irrelevant whether the failure originated in the chemistry lab or the injection-molding facility. The manufacturer put a unified product into the stream of commerce, and they are responsible for its collective failure. This article is a deep-dive blueprint on how we, as device lawyers, unearth the hidden flaws, bypass the corporate finger-pointing, and build an airtight, scientifically undeniable case of combination product failure.
The Finger-Pointing Game: Why Drug and Device Manufacturers Blame Each Other
If you want to see a masterclass in corporate self-preservation, watch what happens when a combination product case goes into active litigation. It is a classic, predictable drama where the pharmaceutical company and the medical device manufacturer turn on each other with astonishing ferocity. I once took a deposition of a pharmaceutical company’s Vice President of Quality Assurance. When I asked why the drug wasn't fully delivered to the patient, he shrugged with practiced indifference and said, "Our formulation was pristine. The device manufacturer’s spring was simply out of tolerance; it lacked the mechanical force to push our liquid through the needle." The next week, I deposed the device company's lead engineer, who scoffed and countered, "Our spring was calibrated to their exact specifications. They changed their drug purification process, which increased the fluid's viscosity, without notifying our engineering team. They essentially tried to push cold honey through a microscopic straw."
This corporate finger-pointing is not just a sideshow; it is the core defensive strategy. By creating a cloud of mutual recrimination, the defendants hope to confuse the jury, dilute their own individual culpability, and convince the court that the plaintiff cannot prove precisely whose negligence caused the injury. If the drug maker can blame the hardware, and the hardware maker can blame the formulation, they hope the plaintiff will be left holding an empty bag. But as a seasoned plaintiff's attorney, you must recognize this finger-pointing for what it truly is: an absolute goldmine. When co-defendants start tearing each other apart, they will do seventy percent of your discovery work for you. They will file cross-claims, produce internal memos critiquing each other’s quality control, and point out the exact engineering flaws you need to highlight.
To capitalize on this, you must understand the concept of the "design freeze" in the product development lifecycle. When a combination product is being developed, there is a specific date when the physical design of the device is locked in—the "freeze." However, the biologic drug formulation is often still undergoing clinical trial modifications, stability testing, and manufacturing scale-up long after the hardware design is frozen. This creates an inevitable mismatch. If the pharmaceutical company alters the pH, changes the surfactant concentration, or switches to a different glass vial supplier to save pennies, they can completely alter the friction dynamics inside the syringe. If they do not communicate these changes to the device partner, or if the device partner refuses to re-evaluate the mechanical design because it would delay their commercial launch, a ticking time bomb is placed in the hands of the patient.
+-----------------------------------------------------------------------------+
| INSIDER NOTE |
| The "Residual Drug" Trap |
| |
| Defense experts love to point to a dry, empty syringe barrel post-failure |
| to argue that the full dose was successfully delivered. Do not fall for |
| this. In many spring-loaded autoinjectors, if the needle is bent or clogs |
| mid-injection, the extreme pressure can cause the liquid to bypass the |
| rubber plunger seal and leak backward into the internal housing, eventually |
| evaporating or pooling invisibly. Always demand chemical assay testing of |
| the internal plastic housing to check for drug residues that should have |
| ended up in the patient's body. |
+-----------------------------------------------------------------------------+
Furthermore, you must dig deep into the joint venture and supply agreements between these companies. These documents are highly guarded corporate secrets, often heavily redacted during the initial stages of discovery under the guise of "commercial sensitivity." You must fight aggressively to unredact them. Within these contracts, you will find detailed indemnification clauses, quality agreements, and joint development protocols. These documents will explicitly outline who was responsible for monitoring the drug-device interface, how they agreed to handle field complaints, and who had the final sign-off on design modifications. Often, you will find that the companies actively traded away patient safety margins during contract negotiations to speed up their regulatory submission timelines.
The Viscosity Trap: When Chemistry Clashes with Mechanical Engineering
To truly understand how these systems fail, we must dive into the cold, hard physics of fluid dynamics. This is what I call "The Viscosity Trap." Many modern combination products deliver large-molecule biologics, such as monoclonal antibodies, which are incredibly complex, heavy proteins. Unlike small-molecule drugs (like saline or simple insulin formulations) which behave like water, these biologic formulations are highly viscous, non-Newtonian fluids. They behave more like liquid gel or warm maple syrup. Pushing a highly viscous, protein-rich liquid through a microscopic 27-gauge or 29-gauge needle requires an immense amount of mechanical force.
This is where the engineering clashes violently with the chemistry. To achieve a rapid, painless injection (typically under 10 seconds), the device must use a highly compressed, heavy-duty stainless steel spring. When the patient presses the activation button, that spring releases its stored energy instantly, slamming a plunger forward against the rubber stopper of a glass syringe. This sudden impact creates a massive spike in hydraulic
[Ethics Watch] Ensuring Transparent Client Communication Regarding Settlement Risks And OddsThe Combination Products Handbook by Greenlight Guru
Title: The Combination Products Handbook
Channel: Greenlight Guru
[Data Insight] Over 150,000 Avoidable Delivery Injuries Occur Annually Across U.S. Hospitals
Combination Products Reporting Device Information and Malfunctions - Pharmacovigilance 2020 by U.S. Food and Drug Administration
Title: Combination Products Reporting Device Information and Malfunctions - Pharmacovigilance 2020
Channel: U.S. Food and Drug Administration
How Do Lawyers Prove a Medical Device Defect by Legal & Funding Resources
Title: How Do Lawyers Prove a Medical Device Defect
Channel: Legal & Funding Resources
